Key result
Trophoblast stem-cell-derived exosomes alleviated doxorubicin-induced cardiac injury by decreasing cardiomyocyte apoptosis and improving cardiac function via the let-7i/YAP pathway.
Why the study?
Although trophoblast stem cells play a cardioprotective role in heart failure, whether trophoblast stem-cell-derived exosomes protect against cardiac injury remains unclear.
Do trophoblast stem-cell-derived exosomes improve cardiac function and reduce apoptosis in doxorubicin-induced dilated cardiomyopathy models?
Do trophoblast stem-cell-derived exosomes improve cardiac function and reduce apoptosis in doxorubicin-induced dilated cardiomyopathy models?
Trophoblast stem-cell-derived exosomes protect against doxorubicin-induced dilated cardiomyopathy in preclinical models by transferring let-7i and silencing the YAP signaling pathway.
Exosome therapy remains investigational for doxorubicin cardiotoxicity; leaves open translation from preclinical models to patients.
Trophoblast stem cells (TSCs) have been confirmed to play a cardioprotective role in heart failure. However, whether TSC-derived exosomes (TSC-exos) can protect against cardiac injury remains unclear. In the present study, TSC-exos were isolated from the supernatant of TSCs using the ultracentrifugation method and characterized by transmission electron microscopy and western blotting. Utilizing the public Gene Expression Omnibus (GEO) database, we found that let-7i and Yes-associated protein 1 (YAP) could participate in the development of heart failure. In vitro , AC16 cardiomyocytes subjected to doxorubicin (DOX) were treated with TSC-exos or let-7i mimic. Flow cytometry showed that TSC-exos and let-7i both decreased cardiomyocyte apoptosis. In vivo , mice that were intraperitoneally injected into DOX received either PBS, TSC-exos, or AAV9-let7i up for let-7i overexpression. Mice receiving TSC-exos and AAV9-let7i up showed improved cardiac function and decreased inflammatory responses, accompanied by downregulated YAP signaling. Mechanistically, TSC-exos could transfer let-7i to cardiomyocytes and silence the YAP signaling pathway. In conclusion, TSC-exos could alleviate DOX-induced cardiac injury via the let-7i/YAP pathway, which sheds new light on the application of TSC-exos as a potential therapeutic tool for heart failure.
No takes yet. Share an insight, caveat, or question.
Ni et al. (2020) studied Doxorubicin-induced dilated cardiomyopathy. Trophoblast stem-cell-derived exosomes (TSC-exos) vs. PBS was evaluated on Cardiac function, inflammatory responses, and cardiomyocyte apoptosis. Trophoblast stem-cell-derived exosomes alleviated doxorubicin-induced cardiac injury by decreasing cardiomyocyte apoptosis and improving cardiac function via the let-7i/YAP pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: